Real‐world Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study
Key Points
This research aims to evaluate how monitoring hydroxychloroquine levels affects lupus outcomes in patients.
Conducted a prospective longitudinal cohort study.
Monitored hydroxychloroquine blood levels in patients with systemic lupus erythematosus.
Focused on patients with estimated glomerular filtration rate (eGFR) ≤75.
Improved control of systemic lupus erythematosus (SLE) was observed with blood level monitoring.
Patients with eGFR ≤75 benefited the most from hydroxychloroquine monitoring.
Abstract
HCQ blood level monitoring could improve SLE control, particularly in patients with eGFR ≤75, and enable optimal HCQ use.
Real‐world Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study | Synapse